Newsletter · · Ashutosh Agarwal

Novo Nordisk Trial Failure Reopens the Obesity Debate as Medicare Starts Paying for GLP-1s - Weekly Pharma / Biotech / Life Sciences Podcast Recap - Week of August 2, 2026

A synthesis of what investor, operator and clinical podcasts said about pharma and biotech for the week of July 26 to August 2, 2026, including Novo Nordisk's cardiovascular outcomes miss, Medicare's BRIDGE pilot covering GLP-1s at a 50 dollar copay, the FDA's peptide-compounding vote, and a wave of practice-changing cancer data.

Weekly Pharma / Biotech / Life Sciences Podcast Recap

Week of July 26 to August 2, 2026: Novo Nordisk's Trial Failure Reopens the Obesity Debate as Medicare Starts Paying for GLP-1s

A quick note on this week's mix before we dive in. The podcast conversation was dominated by two very different clusters. One was obesity and GLP-1 drugs, though most of that came from consumer-health and clinical shows rather than investor debate. The other was cancer-drug data from the ASCO and gynecologic-oncology meetings, which came almost entirely from doctor-education podcasts (OncLive, Research To Practice, Oncology Today), not from stock-picking shows. Underneath those two piles sat a smaller, meatier layer of genuinely investor-focused episodes: BioCentury on a big European biotech buying its first company, CNBC's Fast Money on a Novo Nordisk trial blow-up, The Readout Loud on a failed FDA panel, and reporting on pharma tariffs and drug pricing. Those are where the real money signal was, so that's where this recap spends most of its time.

1. Dominant themes

Theme 1: Novo Nordisk's trial failure reopened the "is the obesity story running out of road?" question

The single loudest investor moment of the week was Novo Nordisk sinking after a trial failure, dissected on CNBC's Fast Money on July 31 with Jared Holtz of Mizuho (CNBC's "Fast Money"). The failed study was one of Novo's cardiovascular "outcome" trials, the kind that has to beat placebo on hard events like heart attacks, not just weight loss. Holtz was careful not to over-read it: "these studies are very tricky… sometimes you just don't get the right patient population and the event rate does not go in your favor," so he "wouldn't write it off completely," though "the odds are obviously very low." The market's reaction was blunt: the panel pegged it as roughly a $15 billion reduction in market cap on the news.

The more interesting takeaway was the framing around what the stock is even worth now. One trader argued the company "gets no credit whatsoever for one of the most successful drug launches in history," a reference to the Wegovy pill, which Holtz called "a monster launch, one of the best we've ever seen." The bull view on the desk was that sentiment is so washed-out that "it won't take a lot to continue to turn it," and that in a broad market sell-off investors "run and hide within health care and staples." The honest bear acknowledgment: "there's no arguing against the fact that there's no momentum in the short term in this name." Both Novo and Eli Lilly were set to report on the Wednesday after the episode, which the traders expected to be a genuine swing event.

Theme 2: The GLP-1 conversation is shifting from "does it work?" to "who pays, and at what price?"

Away from the trading desk, the biggest GLP-1 storyline was affordability and government coverage. Dr. Robert Pearl (former head of the Permanente Group) laid out the numbers on the Fixing Healthcare series (Fixing Healthcare Podcast). US medical spending hit $5.7 trillion last year, up more than 7% for the third year running, roughly twice the pace of GDP or wages, and federal actuaries project it reaching nearly $9 trillion (over 20% of GDP) by 2034. Drug spending was the fastest-growing piece, up 11%, with GLP-1s a named driver.

The concrete, investable news was the new Medicare "BRIDGE" pilot, the first time Medicare will cover GLP-1s for weight loss. Key terms as described:

  • $50/month copay to patients, about 80% below the cash price, under a deal between the Trump administration and manufacturers.
  • The government buys the drugs at about $245/month.
  • It's an 18-month pilot (structured that way because Congress has barred Medicare from covering weight-loss-only drugs), administered by Humana, and sits outside standard Part D, so the roughly $600/year of out-of-pocket cost won't count toward the Part D deductible or the $2,100 annual drug cap.
  • Patients get four choices: Eli Lilly's Zepbound injection or its Fondeo pill, or Novo Nordisk's Wegovy in injectable or pill form. Injectables deliver about 15 to 20% weight loss, pills about 10 to 15%.
  • Eligibility runs from BMI over 35 (otherwise healthy) down to BMI 27 for people with prior heart attacks or strokes. Of Medicare's roughly 70 million members, about 40% (around 30 million) appear eligible, though about 16 million are already getting the drugs via Part D for diabetes, heart disease or sleep apnea.

Pearl's investment-relevant caution: the math on whether GLP-1s actually lower system costs doesn't work yet. It takes 5 to 10 years for lifestyle improvement to pay off in fewer heart attacks and strokes, and for the drugs to be cost-effective the monthly price "would need to be no more than maybe $200 a month," whereas "the lowest retail prices for the brand name drugs… they're double that." His conclusion: rising GLP-1 prescriptions will "increase healthcare costs, not lower them in the future." He also flagged a demand-side wrinkle: because most patients regain weight when they stop, if the $50 price vanishes after 18 months "the pilot will have been a failure." Separately, he noted the ACA exchange squeeze: with enhanced premium support expired, about 4 million of 23 million enrollees have already dropped coverage, risking a "downward spiral" as healthy people leave first.

Theme 3: The peptide "gold rush" and the compounding fight

A theme that ties GLP-1s, telehealth, and FDA policy together: the boom in experimental peptides. The Wall Street Journal's Sara Ashley O'Brien walked through it on The Journal on July 30 (The Journal.). The short version: the success of GLP-1s "opened the floodgates" for a wider wellness craze around injectable peptides (names like BPC-157 and TB-500, marketed together as the "Wolverine stack"), most sold without FDA oversight, often ordered from abroad (frequently China) and mixed at home.

The regulatory pivot is the investable part. Under Biden the FDA put more than a dozen peptides on a "do-not-compound" list in 2023. Now, under HHS Secretary RFK Jr., who says "I'm a big fan of peptides. I've used them myself" and has vowed to "end the war on peptides," an FDA advisory committee last week recommended letting compounding pharmacies make six of seven peptides reviewed. Telehealth players are positioning hard: Hims & Hers bought a peptide-compounding facility in Menlo Park last year, and Noom acquired TaylorMade Compounding (operating in 46 states) this year, with both testifying in favor at the hearing. One analyst pegged the potential telehealth opportunity at more than $2 billion. The counterweight, from the Partnership for Safe Medicines: the vote is "a serious setback for patient safety… Patients won't read the fine print. They will hear one thing. The FDA said yes." Nothing is FDA-approved yet; the committee vote only feeds a future proposed rule, with more peptides up for review early next year.

Theme 4: Pharma tariffs, loud market reaction, quiet corporate shrug

President Trump's threat to eventually put a 100% tariff on imported generic medicines got a clear-eyed breakdown on The Ken's Daybreak (Daybreak). The market moved immediately even though the tariff doesn't bite for two years: India's Nifty Pharma index fell more than 1%, Sun Pharma about 1%, and Cipla nearly 2%. The stakes: India supplies nearly 50% of US generics and exports $8 to 9 billion of pharma to the US a year, and generics are 90% of US prescriptions.

The timeline as described: 100% on generics starting August 1, 2028, rising to 200% in 2029 for anyone who hasn't shifted manufacturing to the US (this follows an April move putting 100% on patented pharma ingredients, with generics then exempted). The corporate reaction was notably relaxed. Dr. Reddy's CEO Erez Israeli, despite North America being a third of the company's revenue, said flatly, "we are not going to invest because of tariffs. We are going to invest because it's good business." The reasoning from multiple analysts: building a viable US generics plant takes at least five years, not two; Indian manufacturing is 40 to 60% cheaper, so a cost advantage may survive even with tariffs; and, crucially, moving the final step to the US doesn't fix the real dependency, since China controls the key starting materials for 94% of amoxicillin, 74% of heparin, and 70% of acetaminophen. A Yale study cited estimated a worldwide 100% tariff would raise finished-drug prices about 30%, roughly $21 on a typical $70 prescription, landing on categories like birth control, antidepressants, and blood-pressure drugs. The named potential winners: Aurobindo Pharma (bought US firm Lannett, with an Indiana plant that can scale to about 4 billion doses a year) and Senores (US-approved product count doubled from 26 to 51 in a year).

Theme 5: A wave of practice-changing cancer data from ASCO and the gynecologic-oncology meeting

By sheer episode count, oncology was the largest cluster, but almost all from clinical-education shows rather than investor podcasts, so treat these as pipeline and data context rather than stock calls. The standouts, with makers added where the drug is well known:

  • Breast cancer ADCs (antibody-drug conjugates): On OncLive, Dr. Paolo Tarantino of Dana-Farber said Destiny Breast 09 data made trastuzumab deruxtecan (T-DXd, AstraZeneca/Daiichi Sankyo) plus pertuzumab the new preferred first-line for HER2-positive disease, hitting about 40 months progression-free survival versus about 26 months for the old standard, with roughly 80% of patients progression-free at two years (OncLive® On Air).
  • Prostate cancer: On Oncology Data Advisor, Dr. Stephen Freedland called both TALAPRO-3 and PROTEUS practice-changing. TALAPRO-3 (talazoparib, Pfizer, plus enzalutamide) showed a 52% reduction in radiographic progression and 23% better survival in HRR-deficient hormone-sensitive prostate cancer (Oncology Data Advisor).
  • PD-L1/VEGF bispecifics in lung cancer, the most direct China-biotech read-through: on OncLive, Dr. Solange Peters said these bispecific antibodies (the recognizable one being ivonescimab, from Summit Therapeutics/Akeso) showed "unexpectedly high" improvements in progression-free and overall survival versus Merck's pembrolizumab alone, including in hard-to-treat PD-L1-low and negative patients, with a shorter half-life that cuts toxicity (OncLive® On Air).
  • HER2-mutant lung cancer: Dr. Joshua Sabari detailed two newly approved oral HER2 drugs, zongertinib (Boehringer Ingelheim) with a 71% response rate and 12.4-month PFS in second line (77% in first line), which cleared the FDA without a randomized Phase 3, versus sevabertinib, which worked but was much harsher (84% diarrhea, 50% rash) (Research To Practice | Oncology Videos).
  • Colorectal cancer: Dr. Tanios Bekaii-Saab presented final BREAKWATER data, encorafenib (Pfizer) plus cetuximab and chemo significantly extended survival in BRAF-V600E metastatic disease, plus 65 to 70% response rates for KRAS-G12C inhibitors (adagrasib, BMS; sotorasib, Amgen) (OncLive® On Air). Separately, MSI-high colorectal immunotherapy data were striking: a 100% complete clinical response in rectal cancer (AZURE-1, dostarlimab, GSK) and improved 3-year disease-free survival with atezolizumab (Roche) in the ATOMIC trial (Research To Practice | Oncology Videos).
  • Blood cancers: In multiple myeloma, Dr. Shaji Kumar backed CAR-T first then bispecifics like teclistamab (J&J), citing 83% progression-free survival at three years for teclistamab plus daratumumab (MajesTEC-3) (Oncology Brothers). In CLL, Dr. Mazyar Shadman highlighted zanubrutinib plus sonrotoclax (BeOne Medicines, formerly BeiGene) reaching about 90% undetectable minimal residual disease (Research To Practice | Oncology Videos). And OncoPharm reviewed the newly FDA-approved ROS1 lung-cancer drug zidesamtinib (Nuvation Bio), a 44% overall response rate with a "slightly different side effect profile" versus rivals (OncoPharm).

Theme 6: RFK Jr., HHS turmoil, and Medicare drug-subsidy cuts as a policy overhang

Two shows dug into the political backdrop weighing on the whole sector. On PopHealth Week, hosts Fred Goldstein and Greg Masters described RFK Jr.'s "ideological remake of HHS" as an intentional dismantling of public-health infrastructure, arguing his vaccine, fluoride, and raw-milk positions "contradict the chronic disease reduction goals and undermine public trust" (Healthcare NOW Radio). On Paging America, the reporting was that Trump is now pushing RFK Jr. harder on vaccine-autism studies (after earlier being asked to tone it down before the midterms), and, directly relevant to drug demand, that the administration is ending Medicare drug-premium subsidies, resulting in higher out-of-pocket drug costs for enrollees (Paging America).

2. Active debates

Do we even need retatrutide? (And is the market too excited about it?) This was the liveliest genuine two-sided debate of the week, on Fast Money (CNBC's "Fast Money"). Mizuho's Jared Holtz was openly skeptical of the Street's enthusiasm for Lilly's next-gen obesity drug retatrutide: "I've been very, very surprised… because of just the optics of a drug that gives near 30% weight loss with low doses. You can get there with the higher doses that the existing drugs give… to me this is very incremental." His framing of the fork: either retatrutide serves only the very highest-BMI population, "or it cannibalizes the existing sales and winds up not being as big of a blockbuster." The bull side (which he attributes partly to retail investors) is that retatrutide "is going to basically take all of the share and become Lilly's best-selling drug." He also flagged that Lilly's oral GLP-1, Fandeo/Fondeo, has been "relatively disappointing," and that the whole Lilly thesis "has shifted almost entirely to the pipeline."

The retatrutide "biologic" fight, a bigger deal than it looks. On the consumer-focused On The Pen, host Dave Knapp argued that Lilly's lawsuit seeking to have retatrutide designated a biologic could set a precedent far beyond one drug (On The Pen GLP-1 News). The stakes: biologic status grants 12 years of market exclusivity versus roughly 5 for a conventional drug, and, depending on how broadly the FDA defines "biologic," could restrict cheap compounded copies of a whole generation of future peptide obesity drugs, from Viking's VK2735 to next-gen GLP-1/GIP molecules. In plain terms, it's a fight over how long Lilly can keep competition and knock-offs out.

China biotech: existential threat or partnership opportunity? The week's clearest voice was Dr. Tan Sian Wee on Inside CVC, and he landed firmly on "manageable and opportunity" (Inside CVC by u-path). He called China's biotech advances "quite frankly astounding," describing automated drug-discovery systems in Shanghai where "all somebody has to do is just drop a test tube… and the machines on the floor will literally take care of the rest." His specifics: automation could cut concept-to-market timelines "from the current five or six year timeframe" down to "probably three years," and CAR-T cell therapies can be made "at a 10th [of] current production cost." His investment logic: cheaper development effectively doubles the number of shots on goal per dollar, so "you double the probability of a successful outcome." Rather than framing it as a threat, he pitched European, Singaporean and Chinese collaboration. Worth flagging as a source-quality note: no US investor podcast took the opposite "China is an existential threat" side this week, so this debate was one-sided in the data.

Is the FDA too tough on rare-disease drugs, or finally being appropriately rigorous? This ran through The Readout Loud's Capricor discussion (The Readout Loud). An FDA official pointedly told patients at the hearing that "rejecting drugs and being a very rigorous regulator is good for patients," because approving something that doesn't work exposes patients to risk. The pushback from the hosts: the agency "still hasn't seen the data" verifying that Sarepta's already-approved Duchenne drug Exondys 51 works, so why hold this "slightly older, sicker" patient population to a tougher standard? It's the central credibility tension for anyone modeling rare-disease approval odds.

Buyers beyond big pharma: has the M&A field permanently widened? BioCentury's editors debated whether the mid-tier of "rising biotechs" (Argenx, Vertex, Genmab, Insmed, Biogen) becoming acquirers changes deal dynamics (BioCentury This Week). The consensus: it gives sellers more options and forces big pharma to watch a wider competitive set, even though the giants can still out-spend anyone. As one editor put it, some assets "can thrive within a smaller organization where they're a close fit instead of… getting lost in a bigger pharma."

3. Stock by stock: bull and bear as guests framed them

A candor note: outside a handful of names, this week's episodes did not deliver clean two-sided bull and bear stock cases, since the oncology shows discussed drugs, not equities. Here's what was genuinely articulated.

Novo Nordisk (NVO): Bull: washed-out sentiment, cheap valuation, and "one of the most successful drug launches in history" (the Wegovy pill) getting "no credit whatsoever"; a defensive place to hide in a market sell-off; the $15B market-cap hit looked commensurate with a lost multi-billion-dollar cardiovascular opportunity, so downside may be limited. Bear: "there's no momentum in the short term"; the trader admitting to being "long and wrong… catching a falling knife"; needs to prove the pipeline has assets beyond obesity. The Q3 print (the day after the episode) was framed as the swing factor (CNBC's "Fast Money").

Eli Lilly (LLY): Bull: the thesis has "shifted almost entirely to the pipeline, including retatrutide," which the Street believes could "take all of the share and become Lilly's best-selling drug"; the biologic-designation lawsuit could lock in 12 years of exclusivity. Bear: the oral drug Fandeo/Fondeo has been "relatively disappointing"; retatrutide may be only "very incremental" over existing drugs and could cannibalize Lilly's own sales; "tougher to call" into the Q3 print (CNBC's "Fast Money"; On The Pen GLP-1 News).

Argenx (ARGX): Bull: BioCentury framed the roughly $2.2 billion, $77/share cash purchase of Forte Biosciences as a smart extension of its winning "pipeline in a product" playbook. Its flagship Vivgart did $1.5 billion in a single quarter, the market cap is above $50 billion and near all-time highs, and the purchase price is barely more than one quarter of Vivgart revenue. Forte brings an anti-CD122 antibody with promising early data in vitiligo, celiac disease, and alopecia, the goal being to become "the premier innovator in immunology" and stretch Vivgart to 10 approvals by 2030. Bear: not really articulated beyond the general risk of paying up for early-stage, single-asset data (BioCentury This Week).

Capricor Therapeutics (CAPR): Bear (dominant): On The Readout Loud, Adam Feuerstein said an FDA advisory panel voted 9 to 3 against recommending approval of Deramiocel for Duchenne muscular dystrophy, after a "blistering" FDA critique disputing the drug's claimed benefits on upper-limb function and heart muscle. The core problem was that Capricor changed its statistical analysis plan mid-study; the FDA used the original, more conservative plan (which didn't hit), and dismissed the company's rosier later versions. Verdict: "the likelihood that this drug gets approved is probably very low," with an FDA decision due by around August 22, 2026. Bull: only the patient community's emotional testimony and the argument that the drug was uniquely tested in older and sicker boys already in wheelchairs (The Readout Loud).

Hims & Hers (HIMS) and Noom (private): Bull: both are pre-positioning for a peptide "gold rush," Hims bought a Menlo Park peptide-compounding facility and Noom bought TaylorMade Compounding (46 states), into a potential $2 billion-plus telehealth market if the FDA loosens peptide rules. Bear: everything hinges on an FDA rule that doesn't exist yet, and patient-safety advocates are lobbying hard against it (The Journal.).

Indian generics (Sun Pharma, Cipla, Dr. Reddy's, Aurobindo, Senores): Bull: tariffs are two years out, US plants take five years to build, and India's 40 to 60% cost advantage plus unavoidable Chinese API dependence mean the threat is more bark than bite for now; Aurobindo and Senores are positioned to gain if rivals get locked out. Bear: razor-thin generic margins mean some manufacturers "may end up exiting specific products entirely," and consumers ultimately pay via roughly 30% higher finished-drug prices (Daybreak).

Summit Therapeutics (SMMT) and ivonescimab: implied read-through only. OncLive's discussion of PD-L1/VEGF bispecifics beating Merck's pembrolizumab "unexpectedly" in first-line lung cancer is the clinical backbone of the Summit and Akeso bull case, though the show framed it as data, not a stock call (OncLive® On Air).

Arvinas (ARVN): BioSpace hosted a discussion of Arvinas' strategy of building an early-stage protein-degrader pipeline and making out-licensing decisions after handing off its lead asset, useful context on "life after the lead asset," though again not framed as a buy or sell (BioSpace).

Regeneron (REGN): Business of Biotech featured Regeneron Genetics Center's Aris Baras on using large human-genetics databases to find drug targets, a strategy piece on the company's discovery engine rather than a valuation call (Business Of Biotech).

4. Notable quotes

  • On retatrutide skepticism: "I've been very, very surprised… because of just the optics of a drug that gives near 30% weight loss with low doses. You can get there with the higher doses that the existing drugs give… to me this is very incremental." Jared Holtz, Mizuho (CNBC's "Fast Money")
  • On the Wegovy pill: "The Wegovi pill has been a monster launch, one of the best we've ever seen." Jared Holtz (CNBC's "Fast Money")
  • On being long Novo: "I've been long and wrong and perhaps I'm just catching a falling knife when I know that I shouldn't. But… if I hold this and look up a year or two from now, I will not regret that decision." Fast Money trader (CNBC's "Fast Money")
  • On GLP-1 cost-effectiveness: "In rough numbers, the monthly cost would need to be no more than maybe $200 a month… so far, the lowest retail prices for the brand name drugs, they're double that." Dr. Robert Pearl (Fixing Healthcare Podcast)
  • On Indian pharma and tariffs: "We are not going to invest because of tariffs. We are going to invest because it's good business." Erez Israeli, CEO of Dr. Reddy's (Daybreak)
  • On China biotech: "What they are doing in terms of their advances in biotechnology development is quite frankly astounding… all somebody has to do is just drop a test tube… and the machines on the floor will literally take care of the rest." Dr. Tan Sian Wee (Inside CVC by u-path)
  • On FDA rigor at the Capricor panel: "[Rejecting drugs and] being a very rigorous regulator is good for patients." FDA official, as relayed on The Readout Loud
  • On the peptide FDA vote: "Patients won't read the fine print. They will hear one thing. The FDA said yes." Head of the Partnership for Safe Medicines, as relayed on The Journal.
  • On AI and expertise in drug discovery: "People are saying, oh, nobody's going to program anymore. But right now, the most effective users of [Claude] code are people who know how to program. And PhDs are still very useful in terms of knowing how to use these tools most effectively." Selina Koch, BioCentury (BioCentury This Week)

5. Catalysts to watch

  • Novo Nordisk and Eli Lilly Q3 earnings (the Wednesday after July 31). Fast Money expected good Novo numbers on Wegovy-pill strength and a possible small guidance bump, but flagged the stock could get "punished" on any miss; Lilly was "tougher to call." All eyes on retatrutide commentary and Fandeo oral GLP-1 traction (CNBC's "Fast Money").
  • Capricor (CAPR) FDA decision by around August 22, 2026 on Deramiocel for Duchenne. After a 9 to 3 negative panel, approval looks unlikely, but the formal decision is the binary event (The Readout Loud).
  • Replimune melanoma FDA advisory panel, flagged as happening the same day as the Readout Loud recording, another rare-disease and rigor test worth tracking (The Readout Loud).
  • FDA peptide rulemaking. The advisory committee's 6-of-7 recommendation feeds a future proposed rule; more peptides come up for review early next year, a direct catalyst for Hims & Hers and Noom (The Journal.).
  • Pharma tariff clock: 100% generics tariff slated for August 1, 2028, 200% in 2029, two years out, but the trigger for any US-reshoring capex decisions by Indian generics makers (Daybreak).
  • Medicare BRIDGE GLP-1 pilot, an 18-month experiment (administered by Humana) whose enrollment and re-authorization will shape the whole GLP-1 volume-versus-price debate; watch for early uptake numbers (Fixing Healthcare Podcast).
  • BioCentury's second-half catalyst scorecard flagged specific readouts: Phase 3 pelacarsen (Novartis/Ionis, Lp(a)) pushed to the second half; a possible PDUFA for GSK and Ionis's hepatitis B functional-cure candidate; and a potential regulatory submission from Arrowhead for its PCSK9 and APOC3 siRNA cardiovascular programs (BioCentury This Week).